The article reviews recent trends in the development of metal-based anticancer drugs, highlighting the exploration of new mechanisms and strategies to overcome the limitations of traditional platinum-based drugs like cisplatin. Key areas discussed include the development of more selective delivery and activation systems for cisplatin-related prodrugs, the discovery of non-covalent interactions with DNA, and the use of metals as scaffolds for constructing complex, three-dimensional structures. The review also covers the emergence of organometallic complexes as promising anticancer agents, particularly in targeting non-classical cellular targets such as proteins and enzymes. These advancements illustrate the potential for more targeted and effective cancer treatments, emphasizing the interdisciplinary nature of research in medicinal inorganic chemistry.The article reviews recent trends in the development of metal-based anticancer drugs, highlighting the exploration of new mechanisms and strategies to overcome the limitations of traditional platinum-based drugs like cisplatin. Key areas discussed include the development of more selective delivery and activation systems for cisplatin-related prodrugs, the discovery of non-covalent interactions with DNA, and the use of metals as scaffolds for constructing complex, three-dimensional structures. The review also covers the emergence of organometallic complexes as promising anticancer agents, particularly in targeting non-classical cellular targets such as proteins and enzymes. These advancements illustrate the potential for more targeted and effective cancer treatments, emphasizing the interdisciplinary nature of research in medicinal inorganic chemistry.